Get the Stockscreener App
1.38
5.48%
-0.08
After Hours:
1.37
-0.010
-0.72%
Inflarx N V stock is traded at $1.38, with a volume of 546.57K.
It is down -5.48% in the last 24 hours and down -12.66% over the past month.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$1.46
Open:
$1.45
24h Volume:
546.57K
Relative Volume:
1.00
Market Cap:
$92.64M
Revenue:
-
Net Income/Loss:
$-46.12M
P/E Ratio:
-1.5969
EPS:
-0.8642
Net Cash Flow:
$-41.02M
1W Performance:
-12.66%
1M Performance:
-12.66%
6M Performance:
+53.33%
1Y Performance:
-5.48%
1-Day Range:
$1.35
$1.51
1-Week Range:
$1.34
$1.63
52-Week Range:
$0.7113
$2.815
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
1.38 | 98.91M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Resumed | H.C. Wainwright | Buy |
| May-29-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx N V Stock (IFRX) Latest News
Will a bounce in InflaRx N.V. offer an exit2025 Technical Patterns & Risk Adjusted Swing Trade Ideas - newser.com
Is InflaRx N.V. stock ready for a breakoutBear Alert & Low Drawdown Momentum Trade Ideas - newser.com
Will InflaRx N.V. (IF0) stock deliver stable dividendsWeekly Investment Recap & AI Optimized Trading Strategy Guides - newser.com
Is now a turning point for InflaRx N.V.Bear Alert & Daily Stock Trend Watchlist - newser.com
Will InflaRx N.V. (IF0) stock test record highs in 2025July 2025 Retail & AI Based Buy/Sell Signal Reports - newser.com
Developing predictive dashboards with InflaRx N.V. data2025 Institutional Moves & Weekly Watchlist for Hot Stocks - newser.com
Is InflaRx N.V. (IF0) stock a good hedge against inflationJuly 2025 Pullbacks & Stepwise Trade Signal Implementation - newser.com
Backtesting results for InflaRx N.V. trading strategiesRecession Risk & Verified Momentum Watchlists - newser.com
Will InflaRx N.V. (IF0) stock attract long term capital inflowsQuarterly Earnings Summary & Verified Momentum Stock Ideas - newser.com
Identifying reversal signals in InflaRx N.V.Earnings Recap Summary & Real-Time Volume Analysis Alerts - newser.com
InflaRx N.V. (NASDAQ:IFRX) Sees Large Increase in Short Interest - Defense World
InflaRx N.V. (NASDAQ:IFRX) Sees Large Growth in Short Interest - MarketBeat
What technical signals suggest for InflaRx N.V. stock2025 EndofYear Setup & Growth Focused Stock Pick Reports - newser.com
What hedge fund moves indicate for InflaRx N.V. (IF0) stockJuly 2025 PostEarnings & Community Consensus Trade Alerts - newser.com
Can machine learning forecast InflaRx N.V. recoveryJuly 2025 Weekly Recap & Weekly High Potential Alerts - newser.com
How InflaRx N.V. (IF0) stock valuation compares with sector2025 Trading Recap & Technical Entry and Exit Alerts - newser.com
Real time scanner hits for InflaRx N.V. explainedJuly 2025 Outlook & Weekly Setup with High ROI Potential - newser.com
What moving averages say about InflaRx N.V.Trend Reversal & Daily Technical Forecast Reports - newser.com
InflaRx N.V. (NASDAQ:IFRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Analyzing InflaRx N.V. with risk reward ratio chartsJuly 2025 Spike Watch & Daily Market Momentum Tracking - newser.com
Will InflaRx N.V. benefit from macro trendsWeekly Stock Report & AI Forecasted Entry/Exit Points - newser.com
Inflarx N V Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):